Second M 3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium

The bronchodilator tiotropium binds not only to its main binding site on the M muscarinic receptor but also to an allosteric site. Here, we have investigated the functional relevance of this allosteric binding and the potential contribution of this behaviour to interactions with long-acting β-adreno...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 2019-08, Vol.176 (16), p.2864-2876
Hauptverfasser: Kistemaker, Loes E M, Elzinga, Carolina R S, Tautermann, Christofer S, Pieper, Michael P, Seeliger, Daniel, Alikhil, Suraya, Schmidt, Martina, Meurs, Herman, Gosens, Reinoud
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2876
container_issue 16
container_start_page 2864
container_title British journal of pharmacology
container_volume 176
creator Kistemaker, Loes E M
Elzinga, Carolina R S
Tautermann, Christofer S
Pieper, Michael P
Seeliger, Daniel
Alikhil, Suraya
Schmidt, Martina
Meurs, Herman
Gosens, Reinoud
description The bronchodilator tiotropium binds not only to its main binding site on the M muscarinic receptor but also to an allosteric site. Here, we have investigated the functional relevance of this allosteric binding and the potential contribution of this behaviour to interactions with long-acting β-adrenoceptor agonists, as combination therapy with anticholinergic agents and β-adrenoceptor agonists improves lung function in chronic obstructive pulmonary disease. ACh, tiotropium, and atropine binding to M receptors were modelled using molecular dynamics simulations. Contractions of bovine and human tracheal smooth muscle strips were studied. Molecular dynamics simulation revealed extracellular vestibule binding of tiotropium, and not atropine, to M receptors as a secondary low affinity binding site, preventing ACh entry into the orthosteric binding pocket. This resulted in a low (allosteric binding) and high (orthosteric binding) functional affinity of tiotropium in protecting against methacholine-induced contractions of airway smooth muscle, which was not observed for atropine and glycopyrrolate. Moreover, antagonism by tiotropium was insurmountable in nature. This behaviour facilitated functional interactions of tiotropium with the β-agonist olodaterol, which synergistically enhanced bronchoprotective effects of tiotropium. This was not seen for glycopyrrolate and olodaterol or indacaterol but was mimicked by the interaction of tiotropium and forskolin, indicating no direct β-adrenoceptor-M receptor crosstalk in this effect. We propose that tiotropium has two binding sites at the M receptor that prevent ACh action, which, together with slow dissociation kinetics, may contribute to insurmountable antagonism and enhanced functional interactions with β-adrenoceptor agonists.
doi_str_mv 10.1111/bph.14707
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_bph_14707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31077341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c182t-98ff29edb22f0628c2a235bcf4e4aec28c0ba3cfa831010c8485df4113ad76a43</originalsourceid><addsrcrecordid>eNo9kE1PAyEQhonR2Fo9-AcMVw9bGWAXejSNX0mNB_XiZQMsWIy7bIA99N-LVp3Lm8z7ZDJ5EDoHsoQyV3rcLoELIg7QvGRT1UzCIZoTQkQFIOUMnaT0QUgpRX2MZgyIEIzDHL09WxOGDj9ihvspGRX94A2O1tgxh4i1Hzo_vOPks8WFzNHrKduEc8A6hsFswxhDtib7MGC9wyVzDKOf-lN05NRnsme_uUCvtzcv6_tq83T3sL7eVAYkzdVKOkdXttOUOtJQaaiirNbGccuVNWVBtGLGKVm-BmIkl3XnOABTnWgUZwt0ub9rYkgpWteO0fcq7log7beftvhpf_wU9mLPjpPubfdP_glhX_pcYnk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Second M 3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kistemaker, Loes E M ; Elzinga, Carolina R S ; Tautermann, Christofer S ; Pieper, Michael P ; Seeliger, Daniel ; Alikhil, Suraya ; Schmidt, Martina ; Meurs, Herman ; Gosens, Reinoud</creator><creatorcontrib>Kistemaker, Loes E M ; Elzinga, Carolina R S ; Tautermann, Christofer S ; Pieper, Michael P ; Seeliger, Daniel ; Alikhil, Suraya ; Schmidt, Martina ; Meurs, Herman ; Gosens, Reinoud</creatorcontrib><description>The bronchodilator tiotropium binds not only to its main binding site on the M muscarinic receptor but also to an allosteric site. Here, we have investigated the functional relevance of this allosteric binding and the potential contribution of this behaviour to interactions with long-acting β-adrenoceptor agonists, as combination therapy with anticholinergic agents and β-adrenoceptor agonists improves lung function in chronic obstructive pulmonary disease. ACh, tiotropium, and atropine binding to M receptors were modelled using molecular dynamics simulations. Contractions of bovine and human tracheal smooth muscle strips were studied. Molecular dynamics simulation revealed extracellular vestibule binding of tiotropium, and not atropine, to M receptors as a secondary low affinity binding site, preventing ACh entry into the orthosteric binding pocket. This resulted in a low (allosteric binding) and high (orthosteric binding) functional affinity of tiotropium in protecting against methacholine-induced contractions of airway smooth muscle, which was not observed for atropine and glycopyrrolate. Moreover, antagonism by tiotropium was insurmountable in nature. This behaviour facilitated functional interactions of tiotropium with the β-agonist olodaterol, which synergistically enhanced bronchoprotective effects of tiotropium. This was not seen for glycopyrrolate and olodaterol or indacaterol but was mimicked by the interaction of tiotropium and forskolin, indicating no direct β-adrenoceptor-M receptor crosstalk in this effect. We propose that tiotropium has two binding sites at the M receptor that prevent ACh action, which, together with slow dissociation kinetics, may contribute to insurmountable antagonism and enhanced functional interactions with β-adrenoceptor agonists.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.14707</identifier><identifier>PMID: 31077341</identifier><language>eng</language><publisher>England</publisher><subject>Acetylcholine - metabolism ; Adrenergic beta-2 Receptor Agonists - pharmacology ; Animals ; Binding Sites ; Bronchodilator Agents - pharmacology ; Cattle ; Cholinergic Antagonists - pharmacology ; Humans ; In Vitro Techniques ; Molecular Dynamics Simulation ; Receptor, Muscarinic M3 - metabolism ; Tiotropium Bromide - pharmacology ; Trachea - drug effects ; Trachea - physiology</subject><ispartof>British journal of pharmacology, 2019-08, Vol.176 (16), p.2864-2876</ispartof><rights>2019 The British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c182t-98ff29edb22f0628c2a235bcf4e4aec28c0ba3cfa831010c8485df4113ad76a43</citedby><cites>FETCH-LOGICAL-c182t-98ff29edb22f0628c2a235bcf4e4aec28c0ba3cfa831010c8485df4113ad76a43</cites><orcidid>0000-0002-7742-8748</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31077341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kistemaker, Loes E M</creatorcontrib><creatorcontrib>Elzinga, Carolina R S</creatorcontrib><creatorcontrib>Tautermann, Christofer S</creatorcontrib><creatorcontrib>Pieper, Michael P</creatorcontrib><creatorcontrib>Seeliger, Daniel</creatorcontrib><creatorcontrib>Alikhil, Suraya</creatorcontrib><creatorcontrib>Schmidt, Martina</creatorcontrib><creatorcontrib>Meurs, Herman</creatorcontrib><creatorcontrib>Gosens, Reinoud</creatorcontrib><title>Second M 3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>The bronchodilator tiotropium binds not only to its main binding site on the M muscarinic receptor but also to an allosteric site. Here, we have investigated the functional relevance of this allosteric binding and the potential contribution of this behaviour to interactions with long-acting β-adrenoceptor agonists, as combination therapy with anticholinergic agents and β-adrenoceptor agonists improves lung function in chronic obstructive pulmonary disease. ACh, tiotropium, and atropine binding to M receptors were modelled using molecular dynamics simulations. Contractions of bovine and human tracheal smooth muscle strips were studied. Molecular dynamics simulation revealed extracellular vestibule binding of tiotropium, and not atropine, to M receptors as a secondary low affinity binding site, preventing ACh entry into the orthosteric binding pocket. This resulted in a low (allosteric binding) and high (orthosteric binding) functional affinity of tiotropium in protecting against methacholine-induced contractions of airway smooth muscle, which was not observed for atropine and glycopyrrolate. Moreover, antagonism by tiotropium was insurmountable in nature. This behaviour facilitated functional interactions of tiotropium with the β-agonist olodaterol, which synergistically enhanced bronchoprotective effects of tiotropium. This was not seen for glycopyrrolate and olodaterol or indacaterol but was mimicked by the interaction of tiotropium and forskolin, indicating no direct β-adrenoceptor-M receptor crosstalk in this effect. We propose that tiotropium has two binding sites at the M receptor that prevent ACh action, which, together with slow dissociation kinetics, may contribute to insurmountable antagonism and enhanced functional interactions with β-adrenoceptor agonists.</description><subject>Acetylcholine - metabolism</subject><subject>Adrenergic beta-2 Receptor Agonists - pharmacology</subject><subject>Animals</subject><subject>Binding Sites</subject><subject>Bronchodilator Agents - pharmacology</subject><subject>Cattle</subject><subject>Cholinergic Antagonists - pharmacology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Molecular Dynamics Simulation</subject><subject>Receptor, Muscarinic M3 - metabolism</subject><subject>Tiotropium Bromide - pharmacology</subject><subject>Trachea - drug effects</subject><subject>Trachea - physiology</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PAyEQhonR2Fo9-AcMVw9bGWAXejSNX0mNB_XiZQMsWIy7bIA99N-LVp3Lm8z7ZDJ5EDoHsoQyV3rcLoELIg7QvGRT1UzCIZoTQkQFIOUMnaT0QUgpRX2MZgyIEIzDHL09WxOGDj9ihvspGRX94A2O1tgxh4i1Hzo_vOPks8WFzNHrKduEc8A6hsFswxhDtib7MGC9wyVzDKOf-lN05NRnsme_uUCvtzcv6_tq83T3sL7eVAYkzdVKOkdXttOUOtJQaaiirNbGccuVNWVBtGLGKVm-BmIkl3XnOABTnWgUZwt0ub9rYkgpWteO0fcq7log7beftvhpf_wU9mLPjpPubfdP_glhX_pcYnk</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Kistemaker, Loes E M</creator><creator>Elzinga, Carolina R S</creator><creator>Tautermann, Christofer S</creator><creator>Pieper, Michael P</creator><creator>Seeliger, Daniel</creator><creator>Alikhil, Suraya</creator><creator>Schmidt, Martina</creator><creator>Meurs, Herman</creator><creator>Gosens, Reinoud</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-7742-8748</orcidid></search><sort><creationdate>201908</creationdate><title>Second M 3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium</title><author>Kistemaker, Loes E M ; Elzinga, Carolina R S ; Tautermann, Christofer S ; Pieper, Michael P ; Seeliger, Daniel ; Alikhil, Suraya ; Schmidt, Martina ; Meurs, Herman ; Gosens, Reinoud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c182t-98ff29edb22f0628c2a235bcf4e4aec28c0ba3cfa831010c8485df4113ad76a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetylcholine - metabolism</topic><topic>Adrenergic beta-2 Receptor Agonists - pharmacology</topic><topic>Animals</topic><topic>Binding Sites</topic><topic>Bronchodilator Agents - pharmacology</topic><topic>Cattle</topic><topic>Cholinergic Antagonists - pharmacology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Molecular Dynamics Simulation</topic><topic>Receptor, Muscarinic M3 - metabolism</topic><topic>Tiotropium Bromide - pharmacology</topic><topic>Trachea - drug effects</topic><topic>Trachea - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kistemaker, Loes E M</creatorcontrib><creatorcontrib>Elzinga, Carolina R S</creatorcontrib><creatorcontrib>Tautermann, Christofer S</creatorcontrib><creatorcontrib>Pieper, Michael P</creatorcontrib><creatorcontrib>Seeliger, Daniel</creatorcontrib><creatorcontrib>Alikhil, Suraya</creatorcontrib><creatorcontrib>Schmidt, Martina</creatorcontrib><creatorcontrib>Meurs, Herman</creatorcontrib><creatorcontrib>Gosens, Reinoud</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kistemaker, Loes E M</au><au>Elzinga, Carolina R S</au><au>Tautermann, Christofer S</au><au>Pieper, Michael P</au><au>Seeliger, Daniel</au><au>Alikhil, Suraya</au><au>Schmidt, Martina</au><au>Meurs, Herman</au><au>Gosens, Reinoud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second M 3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2019-08</date><risdate>2019</risdate><volume>176</volume><issue>16</issue><spage>2864</spage><epage>2876</epage><pages>2864-2876</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>The bronchodilator tiotropium binds not only to its main binding site on the M muscarinic receptor but also to an allosteric site. Here, we have investigated the functional relevance of this allosteric binding and the potential contribution of this behaviour to interactions with long-acting β-adrenoceptor agonists, as combination therapy with anticholinergic agents and β-adrenoceptor agonists improves lung function in chronic obstructive pulmonary disease. ACh, tiotropium, and atropine binding to M receptors were modelled using molecular dynamics simulations. Contractions of bovine and human tracheal smooth muscle strips were studied. Molecular dynamics simulation revealed extracellular vestibule binding of tiotropium, and not atropine, to M receptors as a secondary low affinity binding site, preventing ACh entry into the orthosteric binding pocket. This resulted in a low (allosteric binding) and high (orthosteric binding) functional affinity of tiotropium in protecting against methacholine-induced contractions of airway smooth muscle, which was not observed for atropine and glycopyrrolate. Moreover, antagonism by tiotropium was insurmountable in nature. This behaviour facilitated functional interactions of tiotropium with the β-agonist olodaterol, which synergistically enhanced bronchoprotective effects of tiotropium. This was not seen for glycopyrrolate and olodaterol or indacaterol but was mimicked by the interaction of tiotropium and forskolin, indicating no direct β-adrenoceptor-M receptor crosstalk in this effect. We propose that tiotropium has two binding sites at the M receptor that prevent ACh action, which, together with slow dissociation kinetics, may contribute to insurmountable antagonism and enhanced functional interactions with β-adrenoceptor agonists.</abstract><cop>England</cop><pmid>31077341</pmid><doi>10.1111/bph.14707</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-7742-8748</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2019-08, Vol.176 (16), p.2864-2876
issn 0007-1188
1476-5381
language eng
recordid cdi_crossref_primary_10_1111_bph_14707
source Wiley Online Library - AutoHoldings Journals; MEDLINE; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Acetylcholine - metabolism
Adrenergic beta-2 Receptor Agonists - pharmacology
Animals
Binding Sites
Bronchodilator Agents - pharmacology
Cattle
Cholinergic Antagonists - pharmacology
Humans
In Vitro Techniques
Molecular Dynamics Simulation
Receptor, Muscarinic M3 - metabolism
Tiotropium Bromide - pharmacology
Trachea - drug effects
Trachea - physiology
title Second M 3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T09%3A32%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second%20M%203%20muscarinic%20receptor%20binding%20site%20contributes%20to%20bronchoprotection%20by%20tiotropium&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Kistemaker,%20Loes%20E%20M&rft.date=2019-08&rft.volume=176&rft.issue=16&rft.spage=2864&rft.epage=2876&rft.pages=2864-2876&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.14707&rft_dat=%3Cpubmed_cross%3E31077341%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31077341&rfr_iscdi=true